Figure 3From: Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study Change from baseline at week 10/ ET in AAQoL A) total and B) subscale scores. Back to article page